Below is a three month price history chart comparing the stock performance of MYGN vs.
FORBES: Myriad Genetics Larger Than S&P 500 Component Apollo Group
At the closing bell, MYGN is down about 0.1%, while APOL is trading flat on the day Friday.
In June, Myriad Genetics (nasdaq: MYGN - news - people ) said its Flurizan anti-amyloid drug was totally ineffective in a final-stage trial.
FORBES: Alzheimer's Drug Showdown
应用推荐
模块上移
模块下移
不移动